midazolam and tacrolimus

midazolam has been researched along with tacrolimus in 25 studies

Research

Studies (25)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (4.00)	18.2507
2000's	5 (20.00)	29.6817
2010's	19 (76.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beck, WT; Schuetz, EG; Schuetz, JD	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chalasani, NP; Gorski, JC; Hall, SD; Malireddy, SR; Pinto, AG	1
de Hoon, J; Meersseman, W; Spriet, I; von Winckelmann, S; Willems, L; Wilmer, A	1
Hori, K; Ishibashi, K; Kamimura, H; Kowalski, D; Lee, J; Minematsu, T; Moy, S; Usui, T; Zha, J	1
de Jonge, H; de Loor, H; Kuypers, DR; Vanrenterghem, Y; Verbeke, K	3
Amundsen, R; Åsberg, A; Christensen, H; Ohm, IK	1
Geoghegan, KF; Goosen, TC; Helal, CJ; Hyland, R; Kang, P; Obach, RS; Walker, GS; Walsky, RL; West, M; Zhou, S; Zientek, MA	1
Houjo, T; Ishigai, M; Kato, M; Ogawa, K	1
de Jonge, H; de Loor, H; Elens, L; Kuypers, DR; van Schaik, RH	1
Oda, K; Otsuka, Y; Yamano, K	1
Chapron, B; Collins, C; Phillips, B; Risler, L; Shen, D; Thummel, K	1
de Jonge, H; de Loor, H; Kuypers, DR; Vanhove, T; Verbeke, K	1
Chan, SW; Chu, TT; Fok, BS; Hu, M; Lee, VH; Tomlinson, B; Xiao, Y; Yin, OQ	1
Annaert, P; Bouillon, T; de Loor, H; Kuypers, D; Vanhove, T	1
Dorr, CR; Fisher, J; Guan, W; Israni, AK; Jacobson, PA; Moriarity, BS; Muthusamy, A; Oetting, WS; Remmel, RP; Schuetz, EG; Wu, B; Yasuda, K	1
Annaert, P; de Hoon, J; de Loor, H; Knops, N; Kuypers, DRJ; Vanhove, T	1

Reviews

2 review(s) available for midazolam and tacrolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive care medicine, 2009, Volume: 35, Issue:4 Topics: Acute Disease; Analgesics, Opioid; Anti-Bacterial Agents; Anticonvulsants; Benzodiazepines; Catecholamines; Chronic Disease; Critical Care; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Humans; Immunosuppressive Agents; Intensive Care Units; Midazolam; Tacrolimus	2009

Article

Year

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.

Drug discovery today, 2016, Volume: 21, Issue:4

Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Intensive care medicine, 2009, Volume: 35, Issue:4

Topics: Acute Disease; Analgesics, Opioid; Anti-Bacterial Agents; Anticonvulsants; Benzodiazepines; Catecholamines; Chronic Disease; Critical Care; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Humans; Immunosuppressive Agents; Intensive Care Units; Midazolam; Tacrolimus

2009

Trials

3 trial(s) available for midazolam and tacrolimus

Article	Year
Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1 Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:2 Topics: Adolescent; Adult; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Immunophilins; Ligands; Male; Microsomes, Liver; Midazolam; Middle Aged; Models, Biological; Tacrolimus; Time Factors; Young Adult	2010
Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:6 Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Female; Humans; Kidney Transplantation; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Polymorphism, Single Nucleotide; Solute Carrier Organic Anion Transporter Family Member 1B3; Tacrolimus; Terfenadine; Young Adult	2017
In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. Basic & clinical pharmacology & toxicology, 2019, Volume: 124, Issue:1 Topics: Administration, Oral; Adult; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Prospective Studies; Tacrolimus; Young Adult	2019

Other Studies

20 other study(ies) available for midazolam and tacrolimus

Article	Year
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Molecular pharmacology, 1996, Volume: 49, Issue:2 Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Northern; Cell Line; Clotrimazole; Colonic Neoplasms; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; DNA Primers; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Midazolam; Mixed Function Oxygenases; Molecular Sequence Data; Multigene Family; Phenobarbital; Phenytoin; Polymerase Chain Reaction; Rifampin; Tumor Cells, Cultured; Verapamil	1996
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report. Transplantation proceedings, 2008, Volume: 40, Issue:5 Topics: Adult; Biopsy; Calcineurin Inhibitors; Cholangitis, Sclerosing; Chromatography, High Pressure Liquid; Cyclosporine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Intestine, Small; Liver Transplantation; Male; Mass Spectrometry; Midazolam; Tacrolimus	2008
In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:3 Topics: Adult; Calcineurin; Calcineurin Inhibitors; Case-Control Studies; Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver; Male; Midazolam; Polymorphism, Single Nucleotide; Polypharmacy; Tacrolimus; Transplantation, Homologous	2011
Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:4 Topics: Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Immunosuppressive Agents; In Vitro Techniques; Microsomes, Liver; Midazolam; Nonlinear Dynamics; Substrate Specificity; Tacrolimus; Time Factors	2012
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:9 Topics: Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Genotype; High-Throughput Screening Assays; Humans; Hydroxylation; Kinetics; Liver; Microsomes, Liver; Midazolam; Phenotype; Polymorphism, Genetic; Pyrazoles; Pyrimidines; Recombinant Proteins; Substrate Specificity; Tacrolimus; Testosterone	2012
In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:3 Topics: Cross-Sectional Studies; Cytochrome P-450 CYP3A; Female; Genotype; Hematocrit; Humans; Immunosuppressive Agents; Kidney Transplantation; Linear Models; Linkage Disequilibrium; Male; Midazolam; Middle Aged; Multivariate Analysis; Tacrolimus	2012
A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. Xenobiotica; the fate of foreign compounds in biological systems, 2013, Volume: 43, Issue:5 Topics: Alprazolam; Animals; Cytochrome P-450 CYP3A; Diltiazem; Humans; Liver; Macaca fascicularis; Midazolam; Tacrolimus	2013
Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmacogenomics, 2013, Volume: 14, Issue:12 Topics: Adult; Case-Control Studies; Cytochrome P-450 CYP3A; Gene Expression; Genetic Association Studies; Humans; Inactivation, Metabolic; Kidney Transplantation; Midazolam; Middle Aged; Tacrolimus	2013
The CYP3A422 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. The pharmacogenomics journal, 2015, Volume: 15, Issue:2* Topics: Alleles; Cross-Sectional Studies; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Kidney Transplantation; Male; Midazolam; Middle Aged; Polymorphism, Single Nucleotide; Tacrolimus	2015
In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure. Biopharmaceutics & drug disposition, 2015, Volume: 36, Issue:5 Topics: Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Immunosuppressive Agents; Microsomes, Liver; Midazolam; Models, Biological; Tacrolimus; Testosterone	2015
Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2015, Volume: 18, Issue:1 Topics: Antiviral Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Immunosuppressive Agents; Inhibitory Concentration 50; Microsomes, Liver; Midazolam; NADP; Oligopeptides; Tacrolimus; Time Factors	2015
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. British journal of clinical pharmacology, 2015, Volume: 80, Issue:3 Topics: Area Under Curve; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Hematocrit; Humans; Kidney Transplantation; Longitudinal Studies; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Tacrolimus	2015
Associations of the CYP3A53 and CYP3A41G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:5 Topics: Adult; Asian People; Biomarkers; Cross-Over Studies; Cytochrome P-450 CYP3A; Genotype; Humans; Hydrocortisone; Male; Midazolam; Polymorphism, Genetic; Tacrolimus; Young Adult	2016
CRISPR/Cas9 Genetic Modification of Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:8 Topics: Cell Line; Clustered Regularly Interspaced Short Palindromic Repeats; CRISPR-Cas Systems; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Liver; Male; Midazolam; Middle Aged; Point Mutation; RNA, Messenger; Sequence Deletion; Tacrolimus	2017